Investigator Perspectives on the Prevalence and Clinical Implications of Inaccurate or Misclassified Lymphoma Diagnoses in Community Oncology Practice

Mitchell R Smith, MD, PhD

Track 1: Key components of correctly identifying and grading follicular lymphoma (FL)
Track 2: Diagnostic algorithm for mantle cell lymphoma (MCL)
Track 3: Stepwise process in the diagnosis of diffuse large B-cell lymphoma (DLBCL) and its subtypes
Track 4: Key pathologic features in identifying Hodgkin lymphoma (HL) and incidence of intraobserver variation
Track 5: FISH testing for cytogenetic abnormalities in chronic lymphocytic leukemia (CLL)
Track 6: Incidence of 17p deletion at diagnosis of CLL and after relapse
Track 7: Blood versus bone marrow samples for cytogenetic testing for CLL
Track 8: Minimal residual disease (MRD) assessment in CLL and lymphomas and its application in clinical practice
Track 9: Rates of MRD negativity in patients with CLL treated with venetoclax and/or ibrutinib
Track 10: Challenges in correctly diagnosing T-cell lymphomas (TCLs)
Track 11: CD30 testing in lymphomas
Track 12: Activity and tolerability of brentuximab vedotin in DLBCL and TCLs
Track 13: Phase III ECHELON-1 trial results with front-line brentuximab vedotin for previously untreated Stage III to IV HL
Track 14: Communication between oncologists and pathologists
Track 15: Use of brentuximab vedotin for CD30-negative DLBCL
Track 16: Case: A 62-year-old man with ibrutinib-refractory del(17p) CLL achieves a near-complete response with venetoclax
Track 17: Approach for patients at intermediate to high risk for tumor lysis syndrome (TLS) who are initiating venetoclax treatment
Track 18: Complementary activity of venetoclax and ibrutinib in CLL and investigational strategies evaluating the combination
Track 19: Case: A 70-year-old man who initially underwent treatment for marginal zone lymphoma is diagnosed with Waldenström macroglobulinemia
Track 20: Case: A 68-year-old man who initially underwent treatment for DLBCL for whom repeat pathology now indicates nodular lymphocyte-predominant HL
Track 21: Case: A 35-year-old man about to undergo intensive chemotherapy for Grade IIIb DLBCL for whom a pathologic review reclassifies his disease as an indolent pediatric-type FL

Fernando Cabanillas, MD

Track 1: Key issues affecting diagnostic accuracy and frequency of lymphoma misclassification
Track 2: Changes in WHO diagnostic criteria for lymphomas
Track 3: Case: A 63-year-old man with newly diagnosed CLL who initially underwent treatment with FCR (fludarabine/cyclophosphamide/rituximab) develops a 17p deletion
Track 4: Incidence of 17p deletion at diagnosis versus relapse
Track 5: Detection of 17p deletion
Track 6: Management of venetoclax-associated TLS
Track 7: Case: A 76-year-old woman with differential diagnoses of CLL with Richter's transformation versus DLBCL
Track 8: Case: A 33-year-old woman initially diagnosed with CD30-positive DLBCL, which is revised to HL with nodular sclerosis
Track 9: Testing for and frequency of CD30 positivity in lymphomas
Track 10: Brentuximab vedotin in patients with CD30-negative DLBCL
Track 11: Case: A 51-year-old woman diagnosed with SOX11-negative MCL
Track 12: Common challenges in the diagnosis of TCLs
Track 13: Beyond histology in diagnosing lymphomas: Characterizing relevant biological features
Track 14: Indolent lymphomas that present with clinically aggressive features
Track 15: Clinical approach to patients with clinically discordant low-grade lymphomas

Randy David Gascoyne, MD

Track 1: Critical role of pathologist experience in diagnosing lymphomas
Track 2: Importance of obtaining adequate tumor specimens for diagnosis
Track 3: Technical issues with core needle biopsies
Track 4: Conditions commonly misdiagnosed as cancer
Track 5: Role of assays beyond standard histopathology in diagnosing lymphomas
Track 6: Pitfalls and mistakes with IHC: Failure to order, inadequate staining and misinterpretation
Track 7: Common IHC panels employed by community pathologists
Track 8: Quality and interpretation of CD30 testing
Track 9: FISH testing for cytogenetic abnormalities in CLL and common misdiagnoses
Track 10: Expert second-opinion pathology review of lymphoma in the era of the WHO classification
Track 11: Revision of lymphoma diagnosis at an academic center
Track 12: Intraobserver variation in the grading of FL
Track 13: Case: A 32-year-old patient initially misdiagnosed with peripheral TCL (PTCL), which is revised to ALK-negative anaplastic large cell lymphoma
Track 14: Temporal and tumoral heterogeneity of CD30 expression
Track 15: Changes in CD30 expression in response to treatment with brentuximab vedotin
Track 16: Case: A 47-year-old man initially misdiagnosed with PTCL, which is revised to T-cell and histiocyte-rich B-cell lymphoma
Track 17: Importance of correctly determining DLBCL subtype
Track 18: Diagnosis and treatment of "double-hit" DLBCL
Track 19: Case: A 63-year-old woman initially misdiagnosed with DLBCL, which is revised to angioimmunoblastic-type TCL
Track 20: Case: A 22-year-old man initially misdiagnosed with lymphocyte-rich classical HL, which is revised to nodular lymphocyte-predominant HL
Track 21: Case: A 65-year-old woman initially misdiagnosed with CLL, which is revised to MCL
Track 22: Emergence of del(17p) during CLL evolution
Track 23: Case: A 52-year-old man initially misdiagnosed with DLBCL, which is revised to "double-hit" lymphoma
Track 24: Misdiagnosis of Burkitt lymphoma
Track 25: Extramedullary presentations of acute myeloid leukemia mistakenly interpreted as aggressive lymphoma
Track 26: High-grade plasmablastic cancers misinterpreted as nonhematopoietic tumors
Track 27: Importance of expert review of diagnostic biopsy
Mitchell R Smith, MD, PhD
Professor of Medicine
Associate Center Director
for Clinical Investigations
Division of Hematology
and Oncology
George Washington
Cancer Center
Washington, DC
Fernando Cabanillas, MD
Clinical Professor of Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Medical Director
Auxilio Mutuo Cancer Center
San Juan, Puerto Rico
Randy David Gascoyne, MD
Clinical Professor of Pathology
University of British Columbia
Research Director
Centre for Lymphoid Cancer
Department Head
Lymphoid Cancer Research
British Columbia Cancer Agency
Medical Director, Provincial Lymphoma
Pathology Program
Distinguished Scientist, British
Columbia Cancer Research Centre
Vancouver, British Columbia, Canada
Neil Love, MD
Research To Practice
Miami, Florida